在功能性消化不良症中,热杀 Lacticaseibacillus paracasei HP7 的后生物潜力
Daehyeop Lee1, Ji-Woong Jeong1, Joo-Yun Kim1
1R&BD Center, hy Co., Ltd., Yongin-si 17086, Gyeonggi-do, Republic of Korea.
Journal of microbiology and biotechnology
|October 29, 2025
概括
热杀死的Lacticaseibacillus paracasei HP7 (HP7) 显示了功能性消化不良 (FD) 的后生物潜力. 它改善了肠道运动性,屏障功能,并减少了炎症,这表明它可能是FD管理的安全干预.
科学领域:
- 胃肠道学和微生物学
- 研究益生菌和后生菌在胃肠道疾病中的治疗潜力.
背景情况:
- 功能性消化不良 (FD) 是一种普遍的胃肠道疾病,其特点是肠道运动能力受损和消化功能障碍.
- 目前FD的管理策略存在局限性,需要探索新的治疗方法.
研究的目的:
- 评价热杀死乳酸乳酸菌 (Lacticaseibacillus paracasei) HP7 (HP7) 作为功能性消化不良的后生物干预的疗效.
- 阐明HP7影响胃肠功能和完整性的潜在机制.
主要方法:
- 使用洛佩拉胺诱导的功能性消化不良小鼠模型来评估口服热杀死HP7的效果.
- 在体外研究中,用热杀死HP7,外聚糖 (EPS) 和表面层蛋白 (SLP) 对LPS刺激的Caco-2细胞进行治疗,以检查表皮屏障功能和炎症反应.
- 基因表达分析的重点是平滑肌肉收缩,紧密结合蛋白和炎症标记物.
主要成果:
- 在FD小鼠模型中,热杀死的HP7显著改善了胃排空和调高了与光滑肌肉收缩相关的基因.
- 治疗调节了关键的胃肠道激素 (胃素,GIP,PYY) 并恢复了消化酶活动 (氨酶,氨酸).
- 在体外,HP7成分 (EPS,SLPs) 通过调节紧密结基因并减少炎症基因表达来增强上皮质屏障功能.
结论:
- 热杀死的HP7显示出作为治疗功能性消化不良的后生物剂的巨大潜力.
- 它的机制包括增强胃机动性,加强肠道屏障完整性和减轻炎症.
- 惠普7及其衍生成分为FD提供了一个有前途,安全和有效的治疗途径.
相关概念视频
01:22Pathophysiology of Peptic Ulcer Disease: Injurious Factors
1.1K
Peptic ulcers are sores on the stomach's inner lining and the upper small intestine, which are the result of disruptions in the mucosal layer that houses parietal cells which produce gastric acid, and chief cells which secrete pepsinogen.
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
In the antrum region, G cells secrete the gastrin hormone that binds to gastrin-cholecystokinin-B (CCK2) receptors on parietal and enterochromaffin-like (ECL) cells in the fundic glands. Simultaneously, the vagus nerve releases acetylcholine, which binds...
1.1K
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
532
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
532
01:28Peptic Ulcer Disease II: Pathophysiology
1.9K
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
1.9K
01:30Peptic Ulcer Disease I: Introduction
734
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
734
01:21Drugs for Treatment of Constipation-Predominant IBS
698
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
698